Andoy, Richard D.
HRN: 03-51-00 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/07/2024
CO-AMOXICLAV 625MG (TAB)
06/07/2024
06/14/2024
PO
625mg
Q8
Tonsillar Abscess
Waiting Final Action
Indication: Empiric Type of Infection: Eye, Ear, Nose, Throat, & Mouth Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes